{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:36:17Z","timestamp":1777869377698,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00108-026-02107-3","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:37:08Z","timestamp":1775554628000},"page":"532-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapieprinzipien und Langzeitbetreuung bei Glomerulonephritiden","Treatment principles and long-term management of glomerulonephritides"],"prefix":"10.1007","volume":"67","author":[{"given":"Svjetlana","family":"Lovric","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"2107_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 100:S1\u2013S276","journal-title":"Kidney Int"},{"key":"2107_CR2","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/S0140-6736(16)00272-5","volume":"387","author":"J Floege","year":"2016","unstructured":"Floege\u00a0J, Amann\u00a0K (2016) Primary glomerulonephritides. Lancet 387:2036\u20132048","journal-title":"Lancet"},{"key":"2107_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/ajkd.2000.8966","volume":"36","author":"G D\u2019Amico","year":"2000","unstructured":"D\u2019Amico\u00a0G (2000) Natural history of idiopathic IgA nephropathy. Am J Kidney Dis 36:227\u2013237","journal-title":"Am J Kidney Dis"},{"key":"2107_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2215\/CJN.04160413","volume":"9","author":"C Ponticelli","year":"2014","unstructured":"Ponticelli\u00a0C, Glassock\u00a0RJ (2014) Glomerular diseases: membranous nephropathy. Clin J Am Soc Nephrol 9:609\u2013616","journal-title":"Clin J Am Soc Nephrol"},{"key":"2107_CR5","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"DRW Jayne","year":"2014","unstructured":"Jayne\u00a0DRW et\u00a0al (2014) Randomized trial of rituximab versus cyclophosphamide. N\u00a0Engl J Med 371:1771\u20131780","journal-title":"N Engl J Med"},{"key":"2107_CR6","unstructured":"S3-Leitlinie Diagnose und Therapie von Glomerulonephritiden: https:\/\/register.awmf.org\/de\/leitlinien\/detail\/090-003"},{"key":"2107_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2015.18202","volume":"315","author":"N Tangri","year":"2016","unstructured":"Tangri\u00a0N, Grams\u00a0ME, Levey\u00a0AS et\u00a0al (2016) Multinational assessment of accuracy of equations for predicting risk of kidney failure: a metaanalysis. JAMA 315:164\u2013174","journal-title":"JAMA"},{"key":"2107_CR8","first-page":"176","volume":"14","author":"BH Rovin","year":"2019","unstructured":"Rovin\u00a0BH et\u00a0al (2019) Management and treatment of glomerular diseases. Clin J Am Soc Nephrol 14:176\u2013185","journal-title":"Clin J Am Soc Nephrol"},{"issue":"20","key":"2107_CR9","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"CE Lewis","year":"2021","unstructured":"SPRINT Research Group, Lewis\u00a0CE, Fine\u00a0LJ, Beddhu\u00a0S, Cheung\u00a0AK, Cushman\u00a0WC et\u00a0al (2021) Final Report of a\u00a0Trial of Intensive versus Standard Blood-Pressure Control. N\u00a0Engl J Med 384(20):1921\u20131930","journal-title":"N Engl J Med"},{"issue":"22","key":"2107_CR10","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright","year":"2015","unstructured":"SPRINT Research Group, Wright\u00a0JT, Williamson\u00a0JD, Whelton\u00a0PK, Snyder\u00a0JK, Sink\u00a0KM et\u00a0al (2015) A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N\u00a0Engl J Med 373(22):2103\u20132116","journal-title":"N Engl J Med"},{"issue":"10","key":"2107_CR11","volume":"10","author":"EY Chung","year":"2020","unstructured":"Chung\u00a0EY, Ruospo\u00a0M, Natale\u00a0P, Bolignano\u00a0D, Navaneethan\u00a0SD, Palmer\u00a0SC et\u00a0al (2020) Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 10(10):CD007004","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2107_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.semnephrol.2011.09.003","volume":"31","author":"DC Brater","year":"2011","unstructured":"Brater\u00a0DC (2011) Update in diuretic therapy: clinical pharmacology. Semin Nephrol 31(6):483\u2013494","journal-title":"Semin Nephrol"},{"issue":"1","key":"2107_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0272-6386(12)70179-8","volume":"22","author":"J Radhakrishnan","year":"1993","unstructured":"Radhakrishnan\u00a0J, Appel\u00a0AS, Valeri\u00a0A, Appel\u00a0GB (1993) The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 22(1):135\u2013142","journal-title":"Am J Kidney Dis"},{"key":"2107_CR14","doi-asserted-by":"crossref","unstructured":"Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L. Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev.\u00a010.\u00a0Dezember 2013;(12):CD005425.","DOI":"10.1002\/14651858.CD005425.pub2"},{"issue":"1","key":"2107_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL, Koskinas\u00a0KC, Casula\u00a0M, Badimon\u00a0L et\u00a0al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"15","key":"2107_CR16","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R, Chertow\u00a0GM, Greene\u00a0T, Hou\u00a0FF et\u00a0al (2020) Dapagliflozin in Patients with Chronic Kidney Disease. N\u00a0Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"1","key":"2107_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1681\/ASN.2020030384","volume":"32","author":"JT Kelly","year":"2021","unstructured":"Kelly\u00a0JT, Su\u00a0G, Zhang\u00a0L, Qin\u00a0X, Marshall\u00a0S, Gonz\u00e1lez-Ortiz\u00a0A et\u00a0al (2021) Modifiable Lifestyle Factors for Primary Prevention of CKD: A\u00a0Systematic Review and Meta-Analysis. J\u00a0Am Soc Nephrol JASN 32(1):239\u2013253","journal-title":"J Am Soc Nephrol JASN"},{"issue":"1","key":"2107_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ajcn\/nqac054","volume":"116","author":"H Kim","year":"2022","unstructured":"Kim\u00a0H, Yu\u00a0B, Li\u00a0X, Wong\u00a0KE, Boerwinkle\u00a0E, Seidelmann\u00a0SB et\u00a0al (2022) Serum metabolomic signatures of plant-based diets and incident chronic kidney disease. Am J Clin Nutr 116(1):151\u2013164","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"2107_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.kint.2019.11.027","volume":"97","author":"VK Derebail","year":"2020","unstructured":"Derebail\u00a0VK, Rheault\u00a0MN, Kerlin\u00a0BA (2020) Role of direct oral anticoagulants in patients with kidney disease. Kidney Int 97(4):664\u2013675","journal-title":"Kidney Int"},{"key":"2107_CR20","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41581-023-00766-1","volume":"19","author":"V Petr","year":"2023","unstructured":"Petr\u00a0V, Thurman\u00a0JM (2023) The role of complement in kidney disease. Nat Rev Nephrol 19:771\u2013787. https:\/\/doi.org\/10.1038\/s41581-023-00766-1","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"2107_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin\u00a0LG, Levin\u00a0MJ, Ljungman\u00a0P, Davies\u00a0EG, Avery\u00a0R, Tomblyn\u00a0M et\u00a0al (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis Off Publ Infect Dis Soc Am 58(3):309\u2013318","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"9","key":"2107_CR22","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1007\/s10067-021-05660-4","volume":"40","author":"HC Hsu","year":"2021","unstructured":"Hsu\u00a0HC, Chang\u00a0YS, Hou\u00a0TY, Chen\u00a0LF, Hu\u00a0LF, Lin\u00a0TM et\u00a0al (2021) Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a\u00a0nationwide population-based study. Clin Rheumatol 40(9):3755\u20133763","journal-title":"Clin Rheumatol"},{"issue":"7","key":"2107_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","volume":"377","author":"DL Rolnik","year":"2017","unstructured":"Rolnik\u00a0DL, Wright\u00a0D, Poon\u00a0LC, O\u2019Gorman\u00a0N, Syngelaki\u00a0A, de Paco Matallana\u00a0C et\u00a0al (2017) Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N\u00a0Engl J Med 377(7):613\u2013622","journal-title":"N Engl J Med"},{"issue":"6","key":"2107_CR24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1053\/j.ajkd.2007.03.022","volume":"49","author":"E Imbasciati","year":"2007","unstructured":"Imbasciati\u00a0E, Gregorini\u00a0G, Cabiddu\u00a0G, Gammaro\u00a0L, Ambroso\u00a0G, Del Giudice\u00a0A et\u00a0al (2007) Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis Off J Natl Kidney Found 49(6):753\u2013762","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"8","key":"2107_CR25","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1681\/ASN.2014050459","volume":"26","author":"GB Piccoli","year":"2015","unstructured":"Piccoli\u00a0GB, Cabiddu\u00a0G, Attini\u00a0R, Vigotti\u00a0FN, Maxia\u00a0S, Lepori\u00a0N et\u00a0al (2015) Risk of Adverse Pregnancy Outcomes in Women with CKD. J\u00a0Am Soc Nephrol JASN 26(8):2011\u20132022","journal-title":"J Am Soc Nephrol JASN"},{"issue":"11","key":"2107_CR26","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.2215\/CJN.00130117","volume":"12","author":"K Blom","year":"2017","unstructured":"Blom\u00a0K, Odutayo\u00a0A, Bramham\u00a0K, Hladunewich\u00a0MA (2017) Pregnancy and Glomerular Disease: A Systematic Review of the Literature with Management Guidelines. Clin J Am Soc Nephrol CJASN 12(11):1862\u20131872","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"11","key":"2107_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","volume":"134","author":"JB Levy","year":"2001","unstructured":"Levy\u00a0JB, Turner\u00a0AN, Rees\u00a0AJ, Pusey\u00a0CD (2001) Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134(11):1033\u20131042","journal-title":"Ann Intern Med"},{"key":"2107_CR28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2516150","author":"RA Furie","year":"2026","unstructured":"Furie\u00a0RA, Dall\u2019Era\u00a0M, Vital\u00a0EM et\u00a0al (2026) Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2516150","journal-title":"N Engl J Med"},{"issue":"12","key":"2107_CR29","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie\u00a0R, Rovin\u00a0BH, Houssiau\u00a0F et\u00a0al (2020) Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N\u00a0Engl J Med 383(12):1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"issue":"3","key":"2107_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.103728","volume":"11","author":"M Trillini","year":"2025","unstructured":"Trillini\u00a0M, Portalupi\u00a0V, Gennarini\u00a0A, Surdi\u00a0L, Currado\u00a0A, Maras\u00e0\u00a0M, Podest\u00e0\u00a0MA, Villa\u00a0A, Peracchi\u00a0T, Fidone\u00a0D, Rubis\u00a0N, Diadei\u00a0O, Guarinoni\u00a0C, Casiraghi\u00a0F, Todeschini\u00a0M, Cugini\u00a0D, Carrara\u00a0F, Martinetti\u00a0D, Rizzo\u00a0P, Remuzzi\u00a0G, Ruggenenti\u00a0P (2025) Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy. Kidney Int Rep 11(3):103728. https:\/\/doi.org\/10.1016\/j.ekir.2025.103728","journal-title":"Kidney Int Rep"},{"issue":"7","key":"2107_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ, Bekker\u00a0P, ADVOCATE Study Group (2021) Avacopan for the Treatment of ANCA-Associated Vasculitis. N\u00a0Engl J Med 384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"issue":"10512","key":"2107_CR32","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","volume":"406","author":"D Kavanagh","year":"2025","unstructured":"Kavanagh\u00a0D, Bomback\u00a0AS, Vivarelli\u00a0M et\u00a0al (2025) Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study. Lancet 406(10512):1587\u20131598. https:\/\/doi.org\/10.1016\/S0140-6736(25)01148-1","journal-title":"Lancet"},{"issue":"22","key":"2107_CR33","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","volume":"393","author":"F Fakhouri","year":"2025","unstructured":"Fakhouri\u00a0F, Bomback\u00a0AS, Ariceta\u00a0G et\u00a0al (2025) Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. N\u00a0Engl J Med 393(22):2210\u20132220. https:\/\/doi.org\/10.1056\/NEJMoa2501510","journal-title":"N Engl J Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02107-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02107-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02107-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:37:58Z","timestamp":1777556278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02107-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2107"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02107-3","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Lovric hat Referenten\u2011\/Beraterhonorare von AstraZeneca Germany, Novartis und Sobi erhalten. S.\u00a0Walter gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}